CLS receives new orders from several hospitals in the US
Clinical Laserthermia Systems (CLS) (publ) has, through its subsidiary CLS Americas Inc., received new orders regarding CLS’ single use products for MRI-guided laser ablation from three different hospitals in the US. The largest purchase order comes from University of Texas Medical Branch (UTMB), where CLS single use accessories now is in routine use for laser ablation treatment of early stage tumors in the prostate. The second order also comes from an existing customer, while the third, smaller purchase, comes from a new customer, Desert Medical Imaging, who is going to evaluate CLS’ products. The orders amount to a total value of about 650 000 SEK.
- CLS’ goal for 2017, to initiate sales in the US market, has now been accomplished. We receive repeat orders from demanding customers. This indicates good marks for our products. In the long term I see huge opportunities for us to build a successful business in the US, said Dan Mogren, CCO at CLS. We also have a new customer, Desert Medical Imaging, with long experience from treatment of prostate cancer with MRI-guided laser ablation, who also runs clinical studies in this field. We are very happy that they have chosen to evaluate our products, said Dan Mogren.
In October CLS announced that supplier agreements had been signed with two US hospitals, one being UTMB and the other being a larger, leading hospital. The agreements mean that CLS is an approved supplier to these hospitals. Both hospitals have expressed that they are pleased with CLS’ products and have subsequently now placed new orders.
Read more about Desert Medical Imaging.
This press release has been translated from Swedish. The Swedish text shall govern for all purposes and prevail in case of any discrepancy with the English version.
Lars-Erik Eriksson, CEO, Clinical Laserthermia Systems AB (publ)
Tel: +46 – (0)702 – 90 33 00 E-mail: lee@clinicallaser.se
Clinical Laserthermia Systems AB (publ), develops and sells the TRANBERG®|Thermal Therapy System and specially designed sterile disposable products for safe, gentle and effective treatment of cancerous tumors. The products are marketed for image-guided laser ablation and for treatment with immunostimulating interstitial laser thermotherapy, imILT®. The company, which is headquartered in Lund Sweden and have subsidiaries in Berlin, Germany and Boston, MA,USA, is listed Nasdaq First North under the ticker CLS B. Certified Adviser is Västra Hamnen Corporate Finance. Further information is available on the company’s website: www.clinicallaser.se